Results 91 to 100 of about 27,235 (300)

Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody [PDF]

, 1997
Frank Hartmann, Christoph Renner, Wolfram Jung, Christina Deisting, Marietta Juwana, B Eichentopf, M Kloft, Michael Pfreundschuh   +7 more
openalex   +1 more source

First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study

Head &Neck, EarlyView.
ABSTRACT Background In Europe, pembrolizumab with or without chemotherapy is the recommended first‐line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1.
Alizée Simon, Cyril Abdeddaim, DucTrung Nguyen, Patrice Gallet, Didier Peiffert, Aurélien Lambert, Lionnel Geoffrois   +6 more
wiley   +1 more source

An Engineered Mouse Model That Generates a Diverse Repertoire of Endogenous, High-Affinity Common Light Chain Antibodies

Antibodies
Bispecific antibodies have gained increasing popularity as therapeutics as they enable novel activities that cannot be achieved with monospecific antibodies.
Yinghui Rong, I-Ling Chen, Lance Larrabee, Manali S. Sawant, Germaine Fuh, Patrick Koenig   +5 more
doaj   +1 more source

Inhibition of bispecific monoclonal antibody (bsAb)‐targeted cytolysis by human anti‐mouse antibodies in ovarian carcinoma patients treated with bsAb‐targeted activated T‐lymphocytes [PDF]

, 1995
C. B. H. W. Lamers, Jan W. Gratama, Sven O. Warnaar, G. Stoter, R. L. H. Bolhuis   +4 more
openalex   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinion

International Journal of Cancer, EarlyView.
What's New? Emerging strategies for the treatment of advanced non‐small cell lung cancer (NSCLC) featuring epidermal growth factor receptor (EGFR) mutations are helping improve patient outcomes. Which strategies are optimal to effectively manage EGFR‐mutant NSCLC, however, remains unclear.
Gee‐Chen Chang, Akhil Kapoor, Chee Khoon Lee, Chunxia Su, Daniel Chan, Guia Elena Imelda Ladrera, Hye Ryun Kim, Mostafa Aziz Sumon, Moushumi Suryavanshi, Sita Andarini, Tatsuya Yoshida, Thanyanan Reungwetwattana, Tuan Khoi Nguyen, Pei Jye Voon   +13 more
wiley   +1 more source

Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review)

Клиническая онкогематология, 2019
Therapeutic monoclonal antibodies have long been an effective tool deployed by physicians of different specialties, particularly by oncologists. Bispecific antibodies opened up new horizons in the treatment of cancer as they allow to involve a patient’s ...
ON Solopova, VA Misyurin
doaj   +1 more source

FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy [PDF]

, 1997
Thomas Valerius, Bernhard Stockmeyer, Annemiek B. van Spriel, Robert F. Graziano, Ingrid E. van den Herik–Oudijk, Roland Repp, Yashwant M. Deo, John Lund, Joachim R. Kalden, Martin Gramatzki, Jan G. J. van de Winkel   +10 more
openalex   +1 more source

Targeting T cells against brain tumors with a bispecific ligand‐antibody conjugate [PDF]

, 1998
Edward J. Roy, Bryan K. Cho, Laurie A. Rund, Todd A. Patrick, David M. Kranz   +4 more
openalex   +1 more source

CD86, the double agent: Significance of CD86 expression in B‐cell malignancies

International Journal of Cancer, EarlyView.
Abstract Bypassing the anti‐tumor functions of the immune system is one of the keys to tumor survival. Tumors, especially hematological tumors, produce or express factors that retune T and B cells to inhibit the immune response. Coreceptors CD28 and CTLA‐4, and their ligands, CD80 and CD86, are involved in the immunological synapse and play an ...
Gábor Barna, Gábor Szalóki, Ágnes Márk, Anna Hunyadi, Csilla Kriston   +4 more
wiley   +1 more source